Evaluation of anti-ribosomal P protein immunoassay in Japanese patients with connective tissue diseases: Comparison with an indirect immunofluorescence assay

Y. Muro, Kazumitsu Sugiura, Y. Morita, Y. Tomita

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: To investigate the prevalence of anti-ribosomal P protein (anti-P) antibodies in Japanese patients with connective tissue diseases (CTDs) using enzyme-linked immunosorbent assays (ELISAs) and western blotting (WB) and to evaluate the indirect immunofluorescence (IIF) staining patterns of anti-P-positive sera. Methods: Anti-P antibodies were measured by two different commercially available ELISA kits and WB in 239 outpatients, 99 with systemic sclerosis (SSc), 73 with systemic lupus erythematosus (SLE), 45 with dermatomyositis (DM), and 22 with Sjgren's syndrome (SjS). Sera positive for anti-P antibodies by WB were analysed by IIF. Results: The frequency of positive WB findings in SLE (18/73, 25%) was higher than in other diseases. ELISA kits A and B for anti-P antibodies showed 21% and 43% sensitivity, and 93% and 88% specificity, respectively, for diagnosing SLE, based on the manufacturer's cut-off values. Receiver operating characteristic (ROC) curve analysis, based on positive WB findings, determined a new cut-off threshold but revealed that both ELISA kits still had good diagnostic characteristics. In IIF assays on anti-P antibody positive sera, typical anti-P antibody cytoplasmic staining patterns (n=8) were seen less frequently than other staining patterns (n=17). Conclusions: Routine screening for anti-P antibodies by IIF has low sensitivity. ELISAs using cut-off values established by individual facilities are suitable for detecting anti-P antibodies and provide a tool with good diagnostic characteristics, on a parity with WB.

Original languageEnglish
Pages (from-to)460-463
Number of pages4
JournalScandinavian Journal of Rheumatology
Volume38
Issue number6
DOIs
Publication statusPublished - 27-11-2009
Externally publishedYes

Fingerprint

Connective Tissue Diseases
Ribosomal Proteins
Indirect Fluorescent Antibody Technique
Immunoassay
Western Blotting
Antibodies
Enzyme-Linked Immunosorbent Assay
Systemic Lupus Erythematosus
Staining and Labeling
Serum
Dermatomyositis
Systemic Scleroderma
Parity
ROC Curve
Anti-Idiotypic Antibodies
Outpatients

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

@article{764f69d6e9a44218b0d95df3b9ffc1bf,
title = "Evaluation of anti-ribosomal P protein immunoassay in Japanese patients with connective tissue diseases: Comparison with an indirect immunofluorescence assay",
abstract = "Objectives: To investigate the prevalence of anti-ribosomal P protein (anti-P) antibodies in Japanese patients with connective tissue diseases (CTDs) using enzyme-linked immunosorbent assays (ELISAs) and western blotting (WB) and to evaluate the indirect immunofluorescence (IIF) staining patterns of anti-P-positive sera. Methods: Anti-P antibodies were measured by two different commercially available ELISA kits and WB in 239 outpatients, 99 with systemic sclerosis (SSc), 73 with systemic lupus erythematosus (SLE), 45 with dermatomyositis (DM), and 22 with Sjgren's syndrome (SjS). Sera positive for anti-P antibodies by WB were analysed by IIF. Results: The frequency of positive WB findings in SLE (18/73, 25{\%}) was higher than in other diseases. ELISA kits A and B for anti-P antibodies showed 21{\%} and 43{\%} sensitivity, and 93{\%} and 88{\%} specificity, respectively, for diagnosing SLE, based on the manufacturer's cut-off values. Receiver operating characteristic (ROC) curve analysis, based on positive WB findings, determined a new cut-off threshold but revealed that both ELISA kits still had good diagnostic characteristics. In IIF assays on anti-P antibody positive sera, typical anti-P antibody cytoplasmic staining patterns (n=8) were seen less frequently than other staining patterns (n=17). Conclusions: Routine screening for anti-P antibodies by IIF has low sensitivity. ELISAs using cut-off values established by individual facilities are suitable for detecting anti-P antibodies and provide a tool with good diagnostic characteristics, on a parity with WB.",
author = "Y. Muro and Kazumitsu Sugiura and Y. Morita and Y. Tomita",
year = "2009",
month = "11",
day = "27",
doi = "10.3109/03009740903008767",
language = "English",
volume = "38",
pages = "460--463",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Evaluation of anti-ribosomal P protein immunoassay in Japanese patients with connective tissue diseases

T2 - Comparison with an indirect immunofluorescence assay

AU - Muro, Y.

AU - Sugiura, Kazumitsu

AU - Morita, Y.

AU - Tomita, Y.

PY - 2009/11/27

Y1 - 2009/11/27

N2 - Objectives: To investigate the prevalence of anti-ribosomal P protein (anti-P) antibodies in Japanese patients with connective tissue diseases (CTDs) using enzyme-linked immunosorbent assays (ELISAs) and western blotting (WB) and to evaluate the indirect immunofluorescence (IIF) staining patterns of anti-P-positive sera. Methods: Anti-P antibodies were measured by two different commercially available ELISA kits and WB in 239 outpatients, 99 with systemic sclerosis (SSc), 73 with systemic lupus erythematosus (SLE), 45 with dermatomyositis (DM), and 22 with Sjgren's syndrome (SjS). Sera positive for anti-P antibodies by WB were analysed by IIF. Results: The frequency of positive WB findings in SLE (18/73, 25%) was higher than in other diseases. ELISA kits A and B for anti-P antibodies showed 21% and 43% sensitivity, and 93% and 88% specificity, respectively, for diagnosing SLE, based on the manufacturer's cut-off values. Receiver operating characteristic (ROC) curve analysis, based on positive WB findings, determined a new cut-off threshold but revealed that both ELISA kits still had good diagnostic characteristics. In IIF assays on anti-P antibody positive sera, typical anti-P antibody cytoplasmic staining patterns (n=8) were seen less frequently than other staining patterns (n=17). Conclusions: Routine screening for anti-P antibodies by IIF has low sensitivity. ELISAs using cut-off values established by individual facilities are suitable for detecting anti-P antibodies and provide a tool with good diagnostic characteristics, on a parity with WB.

AB - Objectives: To investigate the prevalence of anti-ribosomal P protein (anti-P) antibodies in Japanese patients with connective tissue diseases (CTDs) using enzyme-linked immunosorbent assays (ELISAs) and western blotting (WB) and to evaluate the indirect immunofluorescence (IIF) staining patterns of anti-P-positive sera. Methods: Anti-P antibodies were measured by two different commercially available ELISA kits and WB in 239 outpatients, 99 with systemic sclerosis (SSc), 73 with systemic lupus erythematosus (SLE), 45 with dermatomyositis (DM), and 22 with Sjgren's syndrome (SjS). Sera positive for anti-P antibodies by WB were analysed by IIF. Results: The frequency of positive WB findings in SLE (18/73, 25%) was higher than in other diseases. ELISA kits A and B for anti-P antibodies showed 21% and 43% sensitivity, and 93% and 88% specificity, respectively, for diagnosing SLE, based on the manufacturer's cut-off values. Receiver operating characteristic (ROC) curve analysis, based on positive WB findings, determined a new cut-off threshold but revealed that both ELISA kits still had good diagnostic characteristics. In IIF assays on anti-P antibody positive sera, typical anti-P antibody cytoplasmic staining patterns (n=8) were seen less frequently than other staining patterns (n=17). Conclusions: Routine screening for anti-P antibodies by IIF has low sensitivity. ELISAs using cut-off values established by individual facilities are suitable for detecting anti-P antibodies and provide a tool with good diagnostic characteristics, on a parity with WB.

UR - http://www.scopus.com/inward/record.url?scp=70450189021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450189021&partnerID=8YFLogxK

U2 - 10.3109/03009740903008767

DO - 10.3109/03009740903008767

M3 - Article

C2 - 19922022

AN - SCOPUS:70450189021

VL - 38

SP - 460

EP - 463

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 6

ER -